Last reviewed · How we verify
Classic DMARDs treatment group
At a glance
| Generic name | Classic DMARDs treatment group |
|---|---|
| Sponsor | Zhang, Xiao, M.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Venlafaxine as Adjunct Therapy in Rheumatoid Arthritis (PHASE2)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Ultrasound to Guide Treatment Decisions in Patients With Rheumatoid Arthritis According to a T2T Approach (NA)
- A Study of Iguratimod in Combination With Tofacitinib in RA Patients (PHASE4)
- Paroxetine Safety and Efficacy in Rheumatoid Arthritis (PHASE3)
- Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Classic DMARDs treatment group CI brief — competitive landscape report
- Classic DMARDs treatment group updates RSS · CI watch RSS
- Zhang, Xiao, M.D. portfolio CI